Domestic equity indices suffered significant pullbacks in the first half of 2022 amid increasing investor concerns of a prolonged economic slowdown. Growth benchmarks were hit hardest given the recent focus on rising rates, although core and value indices across the market capitalization spectrum also notched negative returns during the period. These types of broad-based pullbacks are often conducive to active manager outperformance because, in theory, one of the main benefits of active strategies is protection during down markets. Fund managers are usually able to deliver on this proposition by avoiding speculative stocks with uncertain future cash flows that tend to drop precipitously amid corrections, instead gearing toward high-quality business with pricing power and robust earnings that are able to withstand market swoons. That said, the extent to which managers have been successful in notching returns in excess of their respective benchmarks this year has largely depended on investment style.

In the first six months of 2022, most value-oriented active strategies have done a good job protecting capital. Roughly 67% of managers in the large-cap value space have outperformed their relevant benchmarks, while 90% and 78% have done the same in the mid- and small-cap value spaces, respectively. Core strategies have had similar success. Just over half of large-cap core managers have recorded positive relative returns for the year, while 68% of mid-cap core and 78% of small-cap core managers have outperformed their respective benchmarks. The story is different on the growth side, however, where just 26% of active large-cap, 45% of mid-cap, and 36% of small-cap managers have been able to keep pace with or exceed relevant benchmarks. At a high level, performance of growth indices in 2022 has largely been driven by multiple compression rather than changes in earnings growth or company fundamentals, and active managers are more likely to lag in periods when valuation is the primary driver of market returns.

Marquette recommends allocating between active and passive management based on the efficiency of the underlying market. At the top of the market capitalization spectrum, outperformance has been notoriously difficult in recent history, with roughly two-thirds of all active U.S. large-cap managers trailing the S&P 500 on a trailing 10-year basis regardless of investment style. Mid- and small-cap strategies have had more success generating alpha over longer periods of time given the less efficient nature of those segments of the market, with the majority of managers outperforming their respective indices over the last decade. While even the most capable managers experience periods of underperformance, the case for active management within the U.S. equity space is certainly stronger further down the cap spectrum. Marquette will continue to source best-in-class strategies across all asset classes and recommend these strategies for inclusion in client portfolios where appropriate.

Print PDF > Active Managers: The Mid-Year Report Card

The opinions expressed herein are those of Marquette Associates, Inc. (“Marquette”), and are subject to change without notice. This material is not financial advice or an offer to purchase or sell any product. Marquette reserves the right to modify its current investment strategies and techniques based on changing market dynamics or client needs.

The last Friday in June brings a unique set of challenges for investors managing to the indices of FTSE Russell as the entire family of domestic index products is rebalanced at the end of the second quarter to reflect changes in the U.S. equity markets over the last year. The annual rebalance updates the market capitalization and style profiles of the indices, which then drives shifts in the underlying sector and industry weightings within the benchmarks. After an unprecedented year in equity markets, the most recent reconstitution is worth a deeper look.

While the Russell Reconstitution impacts all Russell indices, the Russell 2000 index ― which tracks small-cap equities within the U.S. ― tends to undergo the most significant overhaul year to year, as newly-public companies are included for the first time and the previous year’s winners move up the market capitalization spectrum. The chart above details the changes in sector weightings for the Russell 2000 Value, Core, and Growth indices resulting from the annual rebalance. The most notable shifts can be seen in the Consumer Discretionary and Health Care sectors, particularly within the Value and Core indices.

The move in Consumer Discretionary is at least in part a product of the meme stock short squeeze earlier this year. While many of the stocks that saw significant price appreciation in recent months (e.g., GameStop) graduated up in market capitalization to the Russell 1000 index, others, like AMC Entertainment, were left behind on the May 7th rank day. A unique aspect of this year’s rebalance is the speculative nature of the trailing 6-month period. On May 7th, AMC Entertainment had a market capitalization of $4.3B, comfortably within the bounds of the small-cap universe as defined by Russell. Since then, the stock is up over 400% to a market capitalization of nearly $30B. It is expected that AMC will remain in the Russell 2000 and Russell 2000 Value indices despite its increased size, making it the largest position in both of these cap-weighted indices, at roughly 0.8% and 1.6%, respectively. This is a double-edged sword for active managers, as performance relative to the small-cap benchmarks may look overly positive or negative, depending on AMC’s path from here.

The changes in the Health Care sector present a different challenge to active managers. The Russell 2000 Value index has historically included a minimal allocation to Biotechnology, an industry synonymous with binary outcomes and companies with little revenue and few tangible products. This year’s rebalance led to a more than 5% increase in the Value benchmark’s weight in Health Care, with Biotechnology making up roughly 70% of that addition. Many small-cap value managers generally avoid biotech due to its inherent risks and do not consider the space an area of expertise. That said, ignoring the now third largest industry in the Russell 2000 Value index may no longer be an option. Relative performance is an important tool in evaluating active managers and understanding what that benchmark represents is imperative. We look forward to seeing how managers adapt to the latest changes.

Print PDF > Russell Reconstitution: AMC Bought Tickets to the Russell 2000

The opinions expressed herein are those of Marquette Associates, Inc. (“Marquette”), and are subject to change without notice. This material is not financial advice or an offer to purchase or sell any product. Marquette reserves the right to modify its current investment strategies and techniques based on changing market dynamics or client needs.